Oppenheimer Holdings' profit margin is lacking behind key peers, particularly Morgan Stanley, who is also a key competitor.

Christopher Nolan's Oppenheimer returned to theaters and is set to overtake Zack Snyder's Batman v. Superman as it climbs toward $1 billion.

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the ...

New York Athletic Commission issues statement regarding controversial call in Tank Davis vs. Lamont Roach fight ...

Shogun star Cosmo Jarvis has joined the cast of Christopher Nolan's The Odyssey - and I don't think the cast list is ever ...

The ending of Apple TV+ thriller Prime Target explained, including if Leo Woodall’s brilliant mathematician survives his ordeal.

Oppenheimer Asset Management Inc. decreased its position in Affirm Holdings, Inc. (NASDAQ:AFRM – Free Report) by 22.8% in the ...

If you missed Oppenheimer in IMAX you can get another chance to see it this weekend with a one-week USA and Canada rerelease ...

Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

David Krumholtz unfortunately developed a rare and extremely dangerous disease, and he feels the need to publicly alert ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...